Skip to main content
SpringerLink
Log in

Preventative measures and prompt recognition are vital when managing dermatological toxicities associated with targeted cancer therapies

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Dermatological toxicities that occur with targeted cancer therapies require prompt identification and management. Depending on the type of toxicity, treatment options include the use of tetracyclines, corticosteroids, local anaesthetics and anti-infective agents, as well as emollients, skin glues, drying sprays and hydrocolloid dressings. Preventative measures are also important.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Peuvrel L, Dréno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014;15(5):425–44.

    Article  PubMed  Google Scholar 

  2. Baas JM, Krens LL, Guchelaar HJ, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev. 2012;38(5):505–14.

    Article  CAS  PubMed  Google Scholar 

  3. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59(4):526–40.

    Article  PubMed  Google Scholar 

  4. Belloni B, Schonewolf N, Rozati S, et al. Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy. 2012;97:191–202.

    Article  CAS  PubMed  Google Scholar 

  5. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396–400.

    Article  PubMed  Google Scholar 

  6. Robert C, Sibaud V, Mateus C, et al. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol. 2012;39(2):227–40.

    Article  CAS  PubMed  Google Scholar 

  7. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.

    Article  CAS  PubMed  Google Scholar 

  8. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res. 2010;16(3):1058–64.

    Article  CAS  PubMed  Google Scholar 

  9. Sibaud V, Delord JP, Chevreau C, et al. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Ann Chir Plast Esthet. 2012;57(2):106–13.

    Article  CAS  PubMed  Google Scholar 

  10. Ishak RS, Aad SA, Kyei A, et al. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. Crit Rev Oncol Hematol. 2014;90(2):152–64.

    Article  PubMed  Google Scholar 

  11. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from the American Journal of Clinical Dermatology 2014;15(5):425−44 [1] by salaried employees of Adis/Springer and was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Preventative measures and prompt recognition are vital when managing dermatological toxicities associated with targeted cancer therapies. Drugs Ther Perspect 31, 128–132 (2015). https://doi.org/10.1007/s40267-015-0193-1

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-015-0193-1

    Search

    Navigation